tadalafil has been researched along with saquinavir in 2 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (saquinavir) | Trials (saquinavir) | Recent Studies (post-2010) (saquinavir) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 1,454 | 256 | 219 |
| Protein | Taxonomy | tadalafil (IC50) | saquinavir (IC50) |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 1.9 | |
| Bile salt export pump | Homo sapiens (human) | 3.9 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (BRU ISOLATE) | 0.016 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 0.0084 | |
| Gag polyprotein | HIV-1 M:B_MN | 0.0131 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 4.05 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.5 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.0066 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 4.273 | |
| Substance-K receptor | Homo sapiens (human) | 6.214 | |
| Thromboxane-A synthase | Homo sapiens (human) | 2.182 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 4.273 | |
| Mu-type opioid receptor | Homo sapiens (human) | 9.625 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 6.951 | |
| Exoribonuclease H | Human immunodeficiency virus 2 | 0.0005 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 1.9 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 1.9 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 1.9 | |
| Genome polyprotein | Human rhinovirus sp. | 0.0005 | |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | 8.26 | |
| Protease | Human immunodeficiency virus 1 | 0.0217 | |
| Protease | Human immunodeficiency virus 1 | 0.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for tadalafil and saquinavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for tadalafil and saquinavir
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |